Assessment of Central Macular Thickness in Diabetic Macular Edema Patients Before and After Anti-VEGF (Ranibizumab) Injection
Year: 2026
Type: article
Abstract: Objective:To assess the central macular thickness and visual acuity in diabetic macular edema (DME) patients pre- and post-anti-vascular endothelial growth factor (VEGF) ranibizumab injection.Methods:A prospective, hospital-based study was conducted at Bansara Eye Care Centre, Shillong, on 33 patients (41 eyes) treated with the first dose of anti-VEGF ranibizumab injection. Pre- and post-treatment assessments included best corrected visual acuity (BCVA) and central macular thickness (CMT) measured using optical coherence tomography (OCT) at baseline, 1 week, 1 month, 3 months, and 6 months.Results:Significant reductions in CMT were observed after the first dose of ranibizumab, with values decreasing from 342.15 ± 103.93µm to 293.7 ± 81.95µm (p=0.000). However, no significant improvement in BCVA was noted post-treatment, with BCVA values remaining relatively unchanged from baseline (0.60 ± 0.40) to 6-month follow-up (0.64 ± 0.57) (p=0.714).Conclusion:Ranibizumab injections resulted in significant reduction in central macular thickness in DME patients, but no significant improvement in visual acuity was observed. These findings suggest that while anti-VEGF treatment may help reduce macular edema, it may not always lead to significant visual improvement. Further studies with extended follow-up and multiple injections are needed to assess the long-term effects on both CMT and visual acuity.
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7220697250